| Symbol | BCYC |
|---|---|
| Name | BICYCLE THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE, CB22 3AT, United Kingdom |
| Telephone | +44 1223261503 |
| Fax | — |
| — | |
| Website | https://www.bicycletherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001761612 |
| Description | Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. Additional info from NASDAQ: |
2026-07-17 20:15
Thompson Travis Alvin 🟢 acquired 60.0K shares (1 derivative) of BICYCLE THERAPEUTICS PLC (BCYC) at $4.21 Transaction Date: Jul 15, 2026 | Filing ID: 000010
Read more
2026-07-17 20:15
Hannay Michael Charles Ferguson 🟢 acquired 60.0K shares (1 derivative) of BICYCLE THERAPEUTICS PLC (BCYC) at $4.21 Transaction Date: Jul 15, 2026 | Filing ID: 000008
Read more
2026-07-17 20:15
Skynner Michael 🟢 acquired 60.0K shares (1 derivative) of BICYCLE THERAPEUTICS PLC (BCYC) at $4.21 Transaction Date: Jul 15, 2026 | Filing ID: 000008
Read more
2026-07-17 20:15
Perry Jennifer Scott 🟢 acquired 60.0K shares (1 derivative) of BICYCLE THERAPEUTICS PLC (BCYC) at $4.21 Transaction Date: Jul 15, 2026 | Filing ID: 000009
Read more
2026-07-07 21:00
Perry Jennifer Scott 🔴 sold 1.4K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $4.34 Transaction Date: Jul 02, 2026 | Filing ID: 000007
Read more
2026-07-07 21:00
Skynner Michael 🔴 sold 2.4K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $4.31 Transaction Date: Jul 02, 2026 | Filing ID: 000006
Read more
2026-07-07 21:00
Lee Kevin 🔴 sold 7.6K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $4.31 Transaction Date: Jul 02, 2026 | Filing ID: 000006
Read more
2026-07-07 21:00
Hannay Michael Charles Ferguson 🔴 sold 1.8K shares of BICYCLE THERAPEUTICS PLC (BCYC) at $4.31 Transaction Date: Jul 02, 2026 | Filing ID: 000006
Read more
2026-07-07 21:00
Thompson Travis Alvin 🔴 sold 923 shares of BICYCLE THERAPEUTICS PLC (BCYC) at $4.31 Transaction Date: Jul 02, 2026 | Filing ID: 000008
Read more
2026-06-18 12:21
(99% Neutral) BICYCLE THERAPEUTICS PLC (BCYC) Announces Regulatory Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07681674 | Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle … | Phase2 | Advanced Solid Tumors | Not_Yet_Recruiting | 2026-08-01 | 2030-05-30 | ClinicalTrials.gov |
| NCT07450859 | A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic… | Phase2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | 2026-03-05 | 2029-05-01 | ClinicalTrials.gov |
| NCT06933329 | Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cel… | Phase2 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2025-07-18 | 2029-02-28 | ClinicalTrials.gov |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial… | Phase2 | Metastatic Urothelial Cancer | Active_Not_Recruiting | 2024-01-24 | 2028-03-01 | ClinicalTrials.gov |
| NCT05644587 | Novel Induction to Buprenorphine/Naloxone | Phase4 | Opioid Use Disorder | Terminated | 2023-02-06 | 2023-11-30 | ClinicalTrials.gov |
| NCT05163041 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2021-11-02 | 2026-12-01 | ClinicalTrials.gov |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Phase1 | Urinary Bladder Neoplasm | Active_Not_Recruiting | 2020-07-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 E… | Phase1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | Active_Not_Recruiting | 2019-11-07 | 2027-07-31 | ClinicalTrials.gov |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | Phase1 | Advanced Solid Tumours | Completed | 2018-01-24 | 2023-11-20 | ClinicalTrials.gov |
Total clinical trials: 9
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nuzefatide pevedotin | Other | Phase PHASE2 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07681674 |
| BT7480 | Other | Phase PHASE2 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07681674 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07681674 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| buprenorphine/naloxone | Other | Phase PHASE4 | Opioid Use Disorder | TERMINATED | NCT05644587 |
| BT1718 | Other | Phase PHASE1 | Advanced Solid Tumours | COMPLETED | NCT03486730 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| BT5528 | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| BT5528 | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| BT5528 | Other | Phase PHASE1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | ACTIVE_NOT_RECRUITING | NCT04180371 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE1 | Urinary Bladder Neoplasm | ACTIVE_NOT_RECRUITING | NCT04561362 |
| BT8009 | Other | Phase PHASE1 | Urinary Bladder Neoplasm | ACTIVE_NOT_RECRUITING | NCT04561362 |
| Pembrolizumab | Other | Phase PHASE1 | Urinary Bladder Neoplasm | ACTIVE_NOT_RECRUITING | NCT04561362 |
| BT8009 | Other | Phase PHASE1 | Urinary Bladder Neoplasm | ACTIVE_NOT_RECRUITING | NCT04561362 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05163041 |
| BT7480 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05163041 |
| Nivolumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05163041 |
| BT7480 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05163041 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06933329 |
| Zelenectide pevedotin | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06933329 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Gemcitabine + cisplatin Or carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| BT8009 | Other | Phase PHASE2 | Metastatic Urothelial Cancer | ACTIVE_NOT_RECRUITING | NCT06225596 |
| nuzefatide pevedotin (BT5528) | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07450859 |
Total products: 97